Ready to transform your molecule lifecycle decisions?
See how Behavior Labs delivers compounding intelligence across every stage of your pharmaceutical program.
Molecule Lifecycle Intelligence
12-stage decision intelligence framework for pharmaceutical brand optimization — from discovery through loss of exclusivity. Every stage has different decisions, different intelligence requirements, and different competitive dynamics.
0
Stage 0 · Early Development
Discovery
Target identification and asset strategy. The decisions made here — which targets to pursue, which mechanisms to explore, which therapeutic areas to enter — define the trajectory of a program for the next decade.
Target Landscape Mapping
Map competitive density across targets, mechanisms, and therapeutic areas to identify genuine white space before committing resources.
Synthetic Phenotyping
Generate synthetic patient populations to model disease phenotypes and predict clinical response patterns without years of real-world data collection.
Knowledge Graph Foundation
Every engagement begins with your molecule's Knowledge Graph — an always-on intelligence substrate that compounds over time.
34%Potential reduction in sample size through phenotype enrichment strategies
1
Stage 1 · Early Development
Preclinical
Readiness and risk validation. De-risk the transition from bench to clinic by stress-testing your development hypothesis against competitive, regulatory, and clinical reality.
Competitive & Regulatory Intelligence
Continuous monitoring with contextualized alerts that connect competitor moves and regulatory changes to your program's strategic implications.
Safety Phenotype Baselines
Generate synthetic safety baselines calibrated to your indication, enabling early risk signal identification before first-in-human dosing.
In Silico Disease Modeling
AI-generated disease models that characterize target patient populations and predict response patterns across subgroups.
2
Stage 2 · Clinical Development
Phase 1
Safety and feasibility assessment. First-in-human decisions set the foundation for everything downstream — dose selection, population, and the competitive clock starts ticking.
Dose-Response Modeling
Integrate preclinical data with synthetic cohort predictions to optimize dose escalation strategies and reduce Phase 1 timelines.
Regulatory Pathway Selection
Analyze FDA and EMA pathway precedents for your mechanism class to select the regulatory strategy that optimizes both speed and label breadth.
Competitive Trial Monitoring
Real-time tracking of competitor Phase 1 programs, enrollment patterns, and emerging safety signals that may impact your development strategy.
3
Stage 3 · Clinical Development
Phase 2
Efficacy and differentiation evidence. The proof-of-concept decision is the first moment where clinical, regulatory, competitive, and commercial strategy must converge.
Endpoint Precedent Analysis
Analyze endpoint acceptance patterns across FDA and EMA for your mechanism class. Benchmark against competitor programs and regulatory precedent.
Enrollment Strategy Optimization
Phenotype-stratified enrollment design with geographic optimization, competitive trial overlap analysis, and enrollment velocity modeling.
Adaptive Design Simulation
Model adaptive trial architectures — interim analysis triggers, sample size re-estimation, dose selection — before committing to a design.
$90MEstimated savings per program through trial design optimization
4
Stage 4 · Pivotal
Phase 3
Pivotal trial and positioning. The most expensive decision in pharmaceutical development. Trial design decisions made here lock in hundreds of millions in cost and years of timeline.
Trial Design Optimization
Integrates synthetic data, CI, and regulatory signals to model adaptive trial designs that balance rigor, regulatory expectations, and competitive urgency.
Synthetic External Control Arms
Generate external control arms from synthetic data and real-world evidence to reduce placebo burden and accelerate enrollment.
Competitive Density Mapping
Visualize the full competitive landscape by indication, line of therapy, and development phase to identify genuine differentiation opportunities.
18 moTimeline compression through adaptive trial design intelligence
5
Stage 5 · Regulatory
Filing
Regulatory and launch preparation. The transition from development to commercialization — where regulatory strategy, market access planning, and launch readiness must align.
Submission Strategy Intelligence
Analyze regulatory reviewer patterns, advisory committee precedents, and competitive submission timing to optimize your filing strategy.
Market Access Groundwork
Begin payer evidence assembly, formulary access modeling, and net price scenario planning before approval — not after.
Launch Readiness Assessment
Connect clinical evidence to commercial positioning, ensuring launch messaging reflects the competitive reality at time of approval.
6
Stage 6 · Commercial
Launch
Market entry and execution. The first 12 months define the brand trajectory. Decision speed matters more here than at any other stage.
Synthetic Audience Testing
Synthetic audiences deliver directionally accurate insight in days — HCP/Patient/Payer panels, message testing, virtual advisory boards.
Messaging & Positioning
AI-powered message development grounded in competitive reality with synthetic audience validation against HCP and payer segments.
Formulary Access Strategy
Payer-specific formulary prediction, net price modeling with rebate scenarios, and evidence gap analysis against payer requirements.
3 wksTo full competitive landscape analysis vs. 3-month consulting cycle
7
Stage 7 · Commercial
Growth
Market expansion and adoption. Expanding indication breadth, geographic reach, and patient share while competitors enter the landscape.
Indication Expansion Intelligence
Model which indication sequences optimize label breadth, pricing corridors, and formulary positioning for your specific program.
Competitive Response Planning
Prioritized action recommendations when a competitor launches, files, or shifts strategy — with modeled impact on your franchise revenue.
KOL & Prescriber Intelligence
Map prescriber adoption patterns, identify key opinion leaders, and track prescribing behavior shifts across therapeutic segments.
8
Stage 8 · Mature
Peak
Value and revenue optimization. Maximizing the franchise while the competitive window is open — every decision trades near-term revenue against long-term franchise value.
Revenue Optimization Modeling
Model the interplay between pricing, volume, payer mix, and competitive dynamics to maximize franchise value through the peak period.
War Gaming Simulations
Scenario-model competitive responses, payer negotiations, and market shifts to stress-test your commercial strategy.
Portfolio Lifecycle Analytics
Track lifecycle position across every product. Identify investment timing, transition triggers, and decision debt accumulation.
9
Stage 9 · Defense
Defend
Competitive defense and protection. When biosimilar filings appear, generic competitors emerge, or next-generation therapies threaten your franchise — the defense window is measured in months, not years.
Filing Surveillance
Monitor ANDA and BPCIA filings, track biosimilar interchangeability designations, and model competitive entry timelines continuously.
Authorized Generic Scenario Planning
Model AG launch timing, pricing, and market share scenarios to determine the optimal window that maximizes franchise value.
Payer Switching Threshold Intelligence
Predict HCP and payer switching thresholds at various discount levels using synthetic persona panels and formulary committee modeling.
4 moAG timing window that can shift hundreds of millions in franchise value
10
Stage 10 · Late Lifecycle
Harvest
Portfolio optimization and planning. Extracting maximum value from the existing franchise while managing the transition to next-generation assets.
Franchise Transition Strategy
Connect LOE defense to next-generation asset positioning. Model patient transition pathways and optimize lifecycle extension timing.
Supply Chain Risk Intelligence
Monitor manufacturing capacity, supply disruption risks, and raw material dependencies across your portfolio and competitor supply chains.
Portfolio Revenue Protection
Quantify revenue at risk across therapeutic areas and prioritize defense investments based on competitive dynamics.
11
Stage 11 · End of Lifecycle
LOE
Transition and continuity. Loss of exclusivity is the most financially impactful lifecycle transition in pharma. The intelligence architecture must start working years before this moment arrives.
Biosimilar Defense Intelligence
Compounding intelligence platform connecting filing surveillance, scenario modeling, payer analysis, and transition planning years before exclusivity expires.
Patient Continuity Planning
Model patient transition pathways, design retention programs, and ensure continuity of care through the brand-to-generic transition.
Next-Generation Pipeline Acceleration
Connect LOE intelligence to your pipeline strategy — ensuring the next-generation asset is positioned to capture the franchise's clinical and commercial equity.
$200B+Branded revenue at risk from LOE through 2030
1 / 12